Strategic Behavioral Health

strategicbh.com

In 2006, Strategic Behavioral Health, LLC was established to deliver high quality behavioral healthcare. Today, we are a growth oriented company with a multistate reach. We utilize a team approach and nurture the professional advancement of our employees. With plans to expand our national footprint, today we own and operate facilities in Colorado, Nevada, New Mexico, North Carolina, Wisconsin and Texas.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

RELEVATE HEALTH ACQUIRES CONNEXION360

Relevate Health | April 26, 2022

news image

Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. The addition of ConneXion360 expands the Relevate Health suite of HCP engagement mar...

Read More

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

news image

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More

HALO LABS LAUNCHED AGGREGATE AND PARTICLE ID, CALLED AURA FOR BIOTHERAPEUTIC DEVELOPMENT

Halo Labs | June 29, 2020

news image

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.Aura is the next generation of the Horizon®, Halo Labs' popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3x106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The...

Read More

CELL AND GENE THERAPY

MODERNA AND ALDEVRON ANNOUNCE EXPANDED COLLABORATION FOR MRNA VACCINE AND THERAPEUTIC PIPELINE

Moderna, Aldevron | May 25, 2021

news image

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA, and recombinant proteins used for vaccines, gene and cell therapy, gene editing, and diagnostic applications, have announced an expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in mRNA therapeutics and vaccines. Aldevron will specifically provide plasmid DNA to act as th...

Read More
news image

MEDICAL

RELEVATE HEALTH ACQUIRES CONNEXION360

Relevate Health | April 26, 2022

Relevate Health solidifies its position as the market leader in Healthcare Professional (HCP) omnichannel engagement with the acquisition of Dallas-based ConneXion360. With this acquisition, Relevate Health now provides its omnichannel solutions and agency services to more than 185 brands from 90 pharmaceutical, biotech, and medical device manufacturers, as well as 24 hospital systems. The addition of ConneXion360 expands the Relevate Health suite of HCP engagement mar...

Read More
news image

ALX RAISES $105M FOR MIDPHASE TRIALS OF CD47 CANCER DRUG

FierceBiotech | February 12, 2020

ALX Oncology has raised $105 million. The series C round will support phase 2 trials of CD47 myeloid checkpoint inhibitor ALX148 in combination with other anti-cancer therapies. Multiple drug developers have gone after CD47 since evidence of its role in the interactions between cancer cells and the immune system became clear. The evidence suggested tumors evade immune attacks by upregulating CD47, leading researchers to posit that blocking the signal will expose cancer cells to a full-force offe...

Read More
news image

HALO LABS LAUNCHED AGGREGATE AND PARTICLE ID, CALLED AURA FOR BIOTHERAPEUTIC DEVELOPMENT

Halo Labs | June 29, 2020

Halo Labs, a life science instrumentation company developing tools for biologics researchers, today announced it has launched its latest aggregate and particle identification system, called Aura™.Aura is the next generation of the Horizon®, Halo Labs' popular Backgrounded Membrane Imaging (BMI) platform. With as little as 5 µL and a linear range of over 3x106 particles/mL, BMI can count, size, and image aggregates and particles in the subvisible range (>1 μm). The...

Read More
news image

CELL AND GENE THERAPY

MODERNA AND ALDEVRON ANNOUNCE EXPANDED COLLABORATION FOR MRNA VACCINE AND THERAPEUTIC PIPELINE

Moderna, Aldevron | May 25, 2021

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Aldevron, LLC, the leading provider of high-quality plasmid DNA, mRNA, and recombinant proteins used for vaccines, gene and cell therapy, gene editing, and diagnostic applications, have announced an expanded collaboration in support of the Moderna COVID-19 Vaccine and additional programs in mRNA therapeutics and vaccines. Aldevron will specifically provide plasmid DNA to act as th...

Read More